DOCSLIB.ORG

Relationships Between Circulating and Intraprostatic Sex Steroid Hormone Concentrations

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Relationships Between Circulating and Intraprostatic Sex Steroid Hormone Concentrations Published OnlineFirst August 22, 2017; DOI: 10.1158/1055-9965.EPI-17-0215 Research Article Cancer Epidemiology, Biomarkers Relationships between Circulating and & Prevention Intraprostatic Sex Steroid Hormone Concentrations Michael B. Cook, Frank Z. Stanczyk, Shannon N. Wood, Ruth M. Pfeiffer, Muhannad Hafi, Carmela C. Veneroso, Barlow Lynch, Roni T. Falk, Cindy Ke Zhou, Shelley Niwa, Eric Emanuel, Yu-Tang Gao, George P. Hemstreet, Ladan Zolfghari, Peter R. Carroll, Michael J. Manyak, Isabell A. Sesterhann, Paul H. Levine, and Ann W. Hsing Abstract Background: Sex hormones have been implicated in prostate Results: Circulating sex steroid hormone concentrations carcinogenesis, yet epidemiologic studies have not provided had low-to-moderate correlations with, and explained small substantiating evidence. We tested the hypothesis that circulat- proportions of variations in, intraprostatic sex steroid hor- ing concentrations of sex steroid hormones reflect intraprostatic mone concentrations. Androstane-3a,17b-diol glucuronide concentrations using serum and adjacent microscopically ver- (3a-diol G) explained the highest variance of tissue concen- ified benign prostate tissue from prostate cancer cases. trations of 3a-diol G (linear regression r2 ¼ 0.21), followed Methods: Incident localized prostate cancer cases scheduled by serum testosterone and tissue dihydrotestosterone (r2 ¼ for surgery were invited to participate. Consented participants 0.10), and then serum estrone and tissue estrone (r2 ¼ 0.09). completed surveys, and provided resected tissues and blood. There was no effect modification by Gleason score, race, Histologic assessment of the ends of fresh frozen tissue confirmed or age. adjacent microscopically verified benign pathology. Sex steroid Conclusions: Circulating concentrations of sex steroid hormones in sera and tissues were extracted, chromatographically hormones are poor surrogate measures of the intraprostatic separated, and then quantitated by radioimmunoassays. Linear hormonal milieu. regression was used to account for variations in intraprostatic Impact: The high exposure misclassification provided by cir- hormone concentrations by age, body mass index, race, and study culating sex steroid hormone concentrations for intraprostatic site, and subsequently to assess relationships with serum hormone levels may partly explain the lack of any consistent association of concentrations. Gleason score (from adjacent tumor tissue), race, circulating hormones with prostate cancer risk. Cancer Epidemiol and age were assessed as potential effect modifiers. Biomarkers Prev; 26(11); 1660–6. Ó2017 AACR. Introduction developed male phenotype, including a small and immature prostate gland (1, 2). The Nobel Prize–winning studies by Prostate cancer has long been hypothesized to have a hor- Huggins and Hodges in 1941 reported that castration and monal pathogenesis. Endogenous sex steroid hormones, par- injection of estrogen cause temporary regression of metastatic ticularly androgens, are undoubtedly essential for normal prostate cancer, implicating androgenic action in prostate can- physiological development, maintenance, and function of the cer progression (3). This led to development of androgen prostate gland. Prepubertally castrated men and male pseudo- deprivation therapy, which remains the mainstay therapy for hermaphrodites with deficient 5a-reductase type II have a mal- men with advanced prostate cancer. Androgen signaling also functions in cell proliferation, differentiation, and apoptosis, and evidence from basic science indicates that androgens, and Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, possibly estrogens, are critically important for prostate carcino- Bethesda, Maryland. genesis (4–6). Note: Supplementary data for this article are available at Cancer Epidemiology, Despite this evidence that implicates sex steroid hormones Biomarkers & Prevention Online (http://cebp.aacrjournals.org/). in prostate cancer pathogenesis, epidemiologic studies that Corresponding Authors: Michael B. Cook, National Cancer Institute, NIH, have assessed prediagnostic circulating hormone concentra- 9609 Medical Center Drive, Rm 7-E106, MSC 9774, Bethesda, MD 20892- tions have not found any consistent association with subse- 9774. Phone: 240-276-7298; E-mail: [email protected]; and Ann W. quent prostate cancer risk (7–9). There are various explana- Hsing, Stanford Cancer Institute, Stanford School of Medicine, Stanford tions for why a true association may have been missed, includ- University, 780 Welch Road, CJ250D, Stanford, CA 94305. E-mail: ing interassay variability, lack of assay standardization, use [email protected]. of a single peripheral blood measurement typically at middle doi: 10.1158/1055-9965.EPI-17-0215 age or later, and case heterogeneity with inclusion of a vari- Ó2017 American Association for Cancer Research. able proportion of indolent disease. Regardless of the true 1660 Cancer Epidemiol Biomarkers Prev; 26(11) November 2017 Downloaded from cebp.aacrjournals.org on September 26, 2021. © 2017 American Association for Cancer Research. Published OnlineFirst August 22, 2017; DOI: 10.1158/1055-9965.EPI-17-0215 Circulating and Intraprostatic Hormones explanation, an inherent assumption of the prior observation- mont Report, U.S. Common Rule) and was preapproved by the al studies is that circulating concentrations are proxies of the required institutional review boards. intraprostatic environment. Testosterone (T) and the more potent metabolite, dihydrotestosterone (DHT), bind the Serum hormone quantitation androgen receptor within the prostate eliciting gene expression Serum levels of androstenedione (A), testosterone (T), DHT, profiles and biological effects that maintain prostate function. 5a-androstane-3a,17b-diol glucuronide (3a-diol G), estrone T is predominantly produced by the testes and released into the (E1), and estradiol (E2) were measured at the University of circulation. DHT, however, is primarily produced within the Southern California (under the direction of FZS) by immunoassay prostate gland, thus circulating DHT precursors [T, androstene- methods during 2007. A, T, DHT, E1, and E2 were measured by RIA dione (A)] and metabolites [5a-androstane-3a,17b-diol glu- with preceding purification steps, including extraction of steroids curonide (3a-diol G)] have traditionally been assessed as with ethyl acetate:hexane (3:2) followed by Celite column par- proxies. The validity of these proxies has not been tested. tition chromatography of individual hormones using ethylene Therefore, we set out to test the hypothesis that circulating glycol as the stationary phase (10–13). For optimum chro- sex steroid hormone concentrations are valid proxies of intra- matographic steroid separation, it was necessary to process A, prostatic concentrations using a large set of blood samples T, E1 and E2 in one assay (hormone set 1 tubes) and DHT in paired with microscopically verified benign tissue samples another assay (hormone set 2 tubes); 0.8 mL serum aliquots were adjacent to prostate cancers. used in each assay. In the first assay, chromatographic elution of A, T, E1, and E2 was achieved with isooctane, 40% toluene in Materials and Methods isooctane, 25% toluene in ethyl acetate, and 40% toluene in isooctane, respectively. In the second assay, DHT was eluted Study population with 10% toluene in isooctane. In each RIA, a highly specific Patients were enrolled in the study between January 2000 and antiserum was used in conjunction with an iodinated radio- April 2004 at five locations: George Washington University Med- ligand, and an appropriate 8-point standard curve was con- ical Center (Washington, DC), University of California at San structed. After an appropriate incubation period, antibody-bound Francisco (San Francisco, CA), Doctor's Community Hospital and unbound hormones were separated by use of a second (Lanham-Seabrook, MD), Washington Hospital Center (Washing- antibody. The resulting raw values were corrected for dilution ton, DC), and INOVA Fairfax Hospital (Falls Church, VA), the factors and procedural losses. latter three of which were primarily coordinated by the staff at 3a-diol G was measured using a commercial 3a-diol G RIA George Washington University Medical Center. Study subject Kit (Diagnostics Systems Laboratories, Webster TX, presently eligibility included: 18 years of age or older; scheduled for radical Beckman-Coulter). The assay measured both isomers of 3a-diol prostatectomy; and newly diagnosed with localized prostate can- G (14). It required no preceding purification steps and was cer. Patients provided written informed consent to be part of the validated extensively in the laboratory. study. Prior to surgery, study patients had standard anthropomet- The assay sensitivities were as follows: 3, 0.5, 1.5, 50, 0.4, and ric measures taken and were administered a questionnaire to 0.2 ng/dL for A, DHT, T, 3a-diol G, E1, and E2, respectively. confirm that they were fasting and had not taken any hormones Coefficients of variation (CV), calculated on the logarithmic scale (e.g., DHEA) or substances that could potentially affect hormone using a mixed model which included an average of four blinded concentrations (e.g., finasteride) in the preceding 24 hours. Study technical replicates from each of seven different individuals subjects also provided 30 mL of blood, which were processed assayed at the same time as the sera for the main analysis across within 4 hours into aliquots of serum,
Load more

Recommended publications
  • Identification and Characterization of Zebrafish 17Beta-HSD Type 1 and Type 3: a Comparative Analysis of Androgen/Estrogen Activity Regulators
    Institut für Experimentelle Genetik GSF-Forschungzentrum für Umwelt und Gesundheit, Neuherberg Identification and characterization of zebrafish 17beta-HSD type 1 and type 3: A comparative analysis of androgen/estrogen activity regulators Rebekka Mindnich Vollständiger Abdruck der von der Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt der Technischen Universität München zur Erlangung des akademischen Grades eines Doktors der Naturwissenschaften genehmigten Dissertation. Vorsitzender: Univ.- Prof. Dr. Bertold Hock Prüfer der Dissertation: 1. Priv.-Doz. Dr. Jerzy Adamski 2. Univ.-Prof. Dr. Johannes Buchner 3. Univ.-Prof. Dr. Wolfgang Wurst Die Dissertation wurde am 30.06.2004 bei der Technischen Universität München eingereicht und durch die Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt am 07.10. 2004 angenommen. Table of contents Table of contents ABSTRACT................................................................................................................................... 7 ZUSAMMENFASSUNG................................................................................................................ 9 ABBREVIATIONS....................................................................................................................... 11 1 INTRODUCTION ................................................................................................................ 13 1.1 THE AIM OF THIS STUDY ...............................................................................................
    [Show full text]
  • Degradation and Metabolite Formation of Estrogen Conjugates in an Agricultural Soil
    Journal of Pharmaceutical and Biomedical Analysis 145 (2017) 634–640 Contents lists available at ScienceDirect Journal of Pharmaceutical and Biomedical Analysis j ournal homepage: www.elsevier.com/locate/jpba Degradation and metabolite formation of estrogen conjugates in an agricultural soil a,b b,∗ Li Ma , Scott R. Yates a Department of Environmental Sciences, University of California, Riverside, CA 92521, United States b Contaminant Fate and Transport Unit, U.S. Salinity Laboratory, Agricultural Research Service, United States Department of Agriculture, Riverside, CA 92507, United States a r t i c l e i n f o a b s t r a c t Article history: Estrogen conjugates are precursors of free estrogens such as 17ß-estradiol (E2) and estrone (E1), which Received 10 April 2017 cause potent endocrine disrupting effects on aquatic organisms. In this study, microcosm laboratory Received in revised form 11 July 2017 ◦ experiments were conducted at 25 C in an agricultural soil to investigate the aerobic degradation and Accepted 31 July 2017 metabolite formation kinetics of 17ß-estradiol-3-glucuronide (E2-3G) and 17ß-estradiol-3-sulfate (E2- Available online 1 August 2017 3S). The aerobic degradation of E2-3G and E2-3S followed first-order kinetics and the degradation rates were inversely related to their initial concentrations. The degradation of E2-3G and E2-3S was extraordi- Keywords: narily rapid with half of mass lost within hours. Considerable quantities of E2-3G (7.68 ng/g) and E2-3S Aerobic degradation 17ß-estradiol-3-glucuronide (4.84 ng/g) were detected at the end of the 20-d experiment, particularly for high initial concentrations.
    [Show full text]
  • Effects of Aminoglutethimide on A5-Androstenediol Metabolism in Postmenopausal Women with Breast Cancer1
    [CANCER RESEARCH 42, 4797-4800, November 1982] 0008-5472/82/0042-0000802.00 Effects of Aminoglutethimide on A5-Androstenediol Metabolism in Postmenopausal Women with Breast Cancer1 Charles E. Bird,2 Valerie Masters, Ernest E. Sterns, and Albert F. Clark Departments of Medicine [C. E. B., V. M.], Surgery [E. E. S.J, and Biochemistry [A. F. C.], Queen s University and Kingston General Hospital, Kingston, Ontario, Canada K7L 2V7 ABSTRACT women. More recently, we (8) and others (18) reported that the production of A5-androstene-3/8,17/8-diol in normal post- A5-Androstene-3/8,1 7/S-diol has potential estrogenic activity menopausal women is approximately 500 to 700 fig/24 hr. because it is known to bind to receptors and translocate to the AG, in combination with hydrocortisone, has been utilized to nucleus of certain estrogen target tissues. Its role in the biology inhibit estrogen production in patients with breast cancer (21 ). of breast cancer is unclear. Aminoglutethimide plus hydrocor This form of therapy has been termed "medical adrenalec tisone ("medical adrenalectomy") has been used to treat post- tomy," and studies suggest that it is as effective as surgical menopausal women with metastatic breast cancer. adrenalectomy. The hydrocortisone shuts off the basal adre- We studied A5-androstene-3/3,17/?-diol metabolism in post- nocortical production of estrogen precursors; AG not only menopausal women with breast cancer before and during slows down steroid biosynthesis at an early step but also aminoglutethimide-plus-hydrocortisone therapy, utilizing the specifically inhibits the aromatization of A4-androstenedione to constant infusion technique.
    [Show full text]
  • Altered Steroid Milieu in AI Resistant Breast Cancer Facilitates AR Mediated Gene Expression Associated with Poor
    Author Manuscript Published OnlineFirst on July 9, 2019; DOI: 10.1158/1535-7163.MCT-18-0791 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 1 Altered steroid milieu in AI resistant breast cancer facilitates AR mediated gene expression associated with poor 2 response to therapy. 3 Short title: Androstenedione drives AR mediated gene expression in AI resistance. 4 Laura Creevey1* ([email protected]) 5 Rachel Bleach1* ([email protected]) 6 Stephen F Madden2 ([email protected]) 7 Sinead Toomey3 ([email protected]) 8 Fiona T Bane1 ([email protected]) 9 Damir Varešlija 1 ([email protected]) 10 Arnold D Hill4 ([email protected]) 11 Leonie S Young1 ([email protected]) 12 ‡Marie McIlroy1 ([email protected]) 13 1. Endocrine Oncology Research Group, Department of Surgery, RCSI, Dublin 2 14 2. Data Science Centre, RCSI, Dublin 2 15 3. Department of Oncology, RCSI, Beaumont Hospital, Dublin 9 16 4. Department of Surgery, RCSI, Beaumont Hospital, Dublin 9 17 * Both authors contributed equally to this manuscript 18 The authors declare there have been no competing interests. 19 ‡Corresponding author: M. McIlroy ([email protected]) 20 Endocrine Oncology Research Group. 21 Department of Surgery, 22 Royal College of Surgeons in Ireland, 23 St. Stephens Green, 24 Dublin 2, 25 Ireland. 26 Tel No: 0035314022286 27 Funding: Health Research Board (HRA-POR-2013-276) (MMcI) and BHCRDT (MMcI). 1 Downloaded from mct.aacrjournals.org on September 23, 2021. © 2019 American Association for Cancer Research. Author Manuscript Published OnlineFirst on July 9, 2019; DOI: 10.1158/1535-7163.MCT-18-0791 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
    [Show full text]
  • 3311 275 a Specific Radioimmunoassay For
    3311 275 A SPECIFIC RADIOIMMUNOASSAY FOR ANDROSTENEDIONE WITH REDUCED BRIDGE-BINDING Gerald D. Nordblom I , Raymond E. Counsell 2 and Barry G. England I 1 Department of Pathology, University of Michigan, Ann Arbor, MI 48109 2 Department of Pharmacology, University of Michigan,Ann Arbor, MI 48109 Received 3-15-85. ABSTRACT Antibody used in a steroid radlolmmunoassay raised against a steroid hapten-carrier protein conjugate may recognize both the hapten and the chemical bridge to the protein. Use of the same bridge in the radio- isotopic label may lead to higher affinity binding to the label than to the native steroid. Inhibition curves under these conditions are shallow and generally not acceptable for radioimmunoassay procedures. We have developed a radloimmunoassay for androstenedlone that employs different bridges a~ the 118 position of the steroid for the protein conjugate and label. The resulting assay has greatly reduced bridge- binding, has an acceptable slope for the standard curve and is very specific as evidenced by low crossreaetivles to other steroids. INTRODUCTION To develop a radloimmunoassay (RIA) for measuring steroids, antibodies for the assay are produced using a steroid hapten-carrier protein conjugate. The resulting antibodies often recognize and demonstrate high affinity binding to both the steroid and the chemical bridge through which the hapten was attached to the carrier protein. This phenomena is referred to as bridge-binding (I-8). Use of 1251 as the radionuclide to produce a labeled trace for the RIA requires that the iodinated functional group, phenol or imidazole, be attached to the steroid with a chemical bridge. However, if the label-bridge is homologous to the conjugate-bridge, the antibodies will have a higher affinity for the label than the native steroid.
    [Show full text]
  • Feminizing Gender-Affirming Hormone Care the Michigan Medicine Approach
    Feminizing Gender-Affirming Hormone Care The Michigan Medicine Approach Our goal is to partner with you to provide the medical care you need in affirming your gender. Our focus is on your lifelong health, safety, and individual medical and transition-related needs. The Michigan Medicine approach is based on the limited but growing medical evidence surrounding gender-affirming hormone care. Based on the available science, we believe mimicking normal physiology will provide you with the best balance of physical and emotional changes and long-term health. This philosophy aligns with current national and international medical guidelines in the care of gender diverse people. We are committed to staying up-to-date with the latest research and medical evidence to ensure you are getting the highest quality care. We know that there are competing approaches to gender-affirming care that are not based on validated scientific evidence. These approaches make scientifically unsubstantiated claims and have unknown short and long-term risks. We are happy to discuss these with you. Below are some answers to questions our patients have asked us about gender- affirming hormone care. We hope the Q&A will help you understand the medical evidence behind our approach to your gender-affirming hormone care, and how it may differ from other approaches, including the approach other well-known clinics in Southeast Michigan. Is there a benefit for monitoring both estrone (E1) and estradiol (E2) levels and aiming for a particular ratio? There are 3 naturally occurring human estrogens: estrone (E1), estradiol (E2), and estriol (E3). Your body naturally balances your estradiol and estrone ratio.
    [Show full text]
  • Hormonal and Immunological Aspects of the Phylogeny of Sex Steroid
    Proc. Nati. Acad. Sci. USA Vol. 77, No. 8, pp. 4578-4582, August 1980 Biochemistry Hormonal and immunological aspects of the phylogeny of sex steroid binding plasma protein (estradiol/dihydrotestosterone/a-fetoprotein) JACK-MICHEL RENOIR, CHRISTINE MERCIER-BODARD, AND ETIENNE-EMILE BAULIEU Unite de Recherches sur le Metabolisme Mol6culaire et la Physiopathologie des St6roides de l'Institut National de la Sante et de la Recherche MWdicale, (U 33), Universite Paris-Sud, DMpartement de Chimie Biologique, 78 rue du GUn6ral Leclerc, 94270 Bicetre, France Communicated by Seymour Lieberman, May 5,1980 ABSTRACT Sex steroid binding plasma protein (Sbp) in man acetate, 1:1 (vol/vol) for estradiol. Nonradioactive steroids were and in monkeys binds the androgens dihydrotestosterone and a gift of Roussel-Uclaf (Romainville) (guaranteed 99% testosterone and the estrogen estradiol with high affinity (Kd tO.5, 1, and 2 nM, respectively). Detailed studies of steroid pure). binding specificity give the same results in all primates, except Chemicals and Animals. Tubing [Visking-Nojax, 8/32 in. that in humans and chimpanzees estrone does not compete for (6.4 mm); from Union Carbide Corporation, New York] was dihydrotestosterone binding. In other mammals, Sbps of Arti- used in equilibrium dialyses. Agarose (Indubiose A 37) was odactyla and Lagomorpha have the same range of affinities for purchased from l'Industrie Biologique Francgaise (Paris), Ul- androgens but they do not bind estradiol to any significant ex- trogel AcA 34 was from LKB (Uppsala, Sweden), and Freund's tent (Kd >280 nM). The dog has an unusual Sbp (Kd for dihy- drotestosterone, 7.1 nM; for estiadiol, 125 nM), and rodents do complete and incomplete adjuvants were from Difco.
    [Show full text]
  • Public Law 108–358 108Th Congress An
    PUBLIC LAW 108–358—OCT. 22, 2004 118 STAT. 1661 Public Law 108–358 108th Congress An Act To amend the Controlled Substances Act to clarify the definition of anabolic steroids and to provide for research and education activities relating to steroids and Oct. 22, 2004 steroid precursors. [S. 2195] Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, Anabolic Steroid Control Act of SECTION 1. SHORT TITLE. 2004. This Act may be cited as the ‘‘Anabolic Steroid Control Act 21 USC 801 note. of 2004’’. SEC. 2. AMENDMENTS TO THE CONTROLLED SUBSTANCES ACT. (a) DEFINITIONS.—Section 102 of the Controlled Substances Act (21 U.S.C. 802) is amended— (1) in paragraph (41)— (A) by realigning the margin so as to align with para- graph (40); and (B) by striking subparagraph (A) and inserting the following: ‘‘(A) The term ‘anabolic steroid’ means any drug or hormonal substance, chemically and pharmacologically related to testosterone (other than estrogens, progestins, corticosteroids, and dehydroepiandrosterone), and includes— ‘‘(i) androstanediol— ‘‘(I) 3β,17β-dihydroxy-5α-androstane; and ‘‘(II) 3α,17β-dihydroxy-5α-androstane; ‘‘(ii) androstanedione (5α-androstan-3,17-dione); ‘‘(iii) androstenediol— ‘‘(I) 1-androstenediol (3β,17β-dihydroxy-5α-androst-1- ene); ‘‘(II) 1-androstenediol (3α,17β-dihydroxy-5α-androst-1- ene); ‘‘(III) 4-androstenediol (3β,17β-dihydroxy-androst-4- ene); and ‘‘(IV) 5-androstenediol (3β,17β-dihydroxy-androst-5- ene); ‘‘(iv) androstenedione— ‘‘(I) 1-androstenedione ([5α]-androst-1-en-3,17-dione); ‘‘(II) 4-androstenedione (androst-4-en-3,17-dione); and ‘‘(III) 5-androstenedione (androst-5-en-3,17-dione); ‘‘(v) bolasterone (7α,17α-dimethyl-17β-hydroxyandrost-4-en- 3-one); ‘‘(vi) boldenone (17β-hydroxyandrost-1,4,-diene-3-one); ‘‘(vii) calusterone (7β,17α-dimethyl-17β-hydroxyandrost-4- en-3-one); VerDate 11-MAY-2000 08:28 Nov 10, 2005 Jkt 029194 PO 00000 Frm 00525 Fmt 6580 Sfmt 6581 C:\STATUTES\2004\29194PT2.001 APPS10 PsN: 29194PT2 118 STAT.
    [Show full text]
  • Steroidogenic Pathways Involved in Androgen Biosynthesis In
    Journal of Steroid Biochemistry & Molecular Biology 158 (2016) 31–37 Contents lists available at ScienceDirect Journal of Steroid Biochemistry & Molecular Biology journal homepage: www.elsevier.com/locate/jsbmb Steroidogenic pathways involved in androgen biosynthesis in eumenorrheic women and patients with polycystic ovary syndrome a,b,1 c,1 c a d Kazuki Saito , Toshiya Matsuzaki , Takeshi Iwasa , Mami Miyado , Hidekazu Saito , e f g h Tomonobu Hasegawa , Keiko Homma , Eisuke Inoue , Yoshimichi Miyashiro , b c a,i a, Toshiro Kubota , Minoru Irahara , Tsutomu Ogata , Maki Fukami * a Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo 157-8535, Japan b Department of Comprehensive Reproductive Medicine, Graduate School, Tokyo Medical and Dental University, Tokyo 113-8510, Japan c Department of Obstetrics and Gynecology, The University of Tokushima Graduate School, Institute of Health Biosciences, Tokushima 770-8503, Japan d Division of Reproductive Medicine, Center for Maternal-Fetal-Neonatal and Reproductive Medicine, National Medical Center for Children and Mothers, Tokyo 157-8535, Japan e Department of Pediatrics, Keio University School of Medicine, Tokyo 160-8582, Japan f Department of Laboratory Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan g Division of Statistical Analysis, Center for Clinical Research and Development, National Center for Child Health and Development, Tokyo 157-8535, Japan h ASKA Pharmaceutical Medical Corporation, Kanagawa 213-8522, Japan i Department of Pediatrics, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan A R T I C L E I N F O A B S T R A C T Article history: The conventional D5 and D4 steroidogenic pathways mediate androgen production in females.
    [Show full text]
  • Androgens in Skin Surface Lipids* Mary Ellen Karunakaran, Ph.D
    THE JOURNAL OF iNVESTIGATIVE DERMATOLOGY Vol. 60 , No.3 Copyrig h t © 1973 by The Williams & Wilkins Co. Printed in U.S.A. ANDROGENS IN SKIN SURFACE LIPIDS* MARY ELLEN KARUNAKARAN, PH.D. , PETER E. POCHI, M.D. , JOHN S. STRAUSS, M.D. , EUGE lA A. VALERIO, M.A., HERBERT H. WOTIZ, PH.D. , AND STANLEY J . CLARK, PH.D ABSTRACT Sebum collected from t high, scalp, back, a nd face skin of adult males was examined for t he presence, in either free or conjugated state, of seven androgens. Estimates of t he quantities present were made by gas chromatographic a nalysis ailer separation of free from conjugated steroids, solvolysis of t he conjugates, preliminary purification by thin-layer c hromatography, and formation of t he t rimethylsil yl derivative of t he hydroxysteroids. Losses during t hese procedures were estimated by measuring t he recovery of 3H -labeled steroids added to t he sebum before treatment. Suggestive evidence was found for t he presence of a ndrostanedione, androstenedione, dihydrotestosterone, androsterone, and dehydroepiandrosterone. The a mounts obtained were much lower t han values that have been reported previously a nd were insufficient for full characterization . Testosterone and etiocholanolone were not detected. A role for t he sebaceous g lands in t he excretion or C 19-steroids in sebum by factors of 3 to 100 of androgenic steroids has been suggested by depending o n t he particular compound. Dubovyi [1] a nd by Oertel and Treiber (2] who analyzed sebum coll ected from t he scalp and MATERIALS AND METHODS thigh , respectively, and reported fi nding micro­ Solvents.
    [Show full text]
  • Physiological and Biochemical Aspects of 17Β-Hydroxysteroid Dehydrogenase Type 2 and 3
    Physiological and Biochemical Aspects of 17β-Hydroxysteroid Dehydrogenase Type 2 and 3 Inauguraldissertation zur Erlangung der Würde eines Doktors der Philosophie vorgelegt der Philosophisch-Naturwissenschaftlichen Fakultät der Universität Basel von Roger Thomas Engeli aus Sulgen (TG), Schweiz Basel, 2017 Originaldokument gespeichert auf dem Dokumentenserver der Universität Basel edoc.unibas.ch Dieses Werk ist lizenziert unter einer Creative Commons Namensnennung-Nicht kommerziell 4.0 International Lizenz. Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät auf Antrag von Prof. Dr. Alex Odermatt und Prof. Dr. Rik Eggen Basel, den 20.06.2017 ________________________ Dekan Prof. Dr. Martin Spiess 2 Table of Contents Table of Contents ............................................................................................................................... 3 Abbreviations ..................................................................................................................................... 4 1. Summary ........................................................................................................................................ 6 2. Introduction ................................................................................................................................... 8 2.1 Steroid Hormones ............................................................................................................................... 8 2.2 Human Steroidogenesis....................................................................................................................
    [Show full text]
  • Label Extension of HERS, HERS II
    Depo®-Estradiol Estradiol cypionate injection, USP WARNINGS: ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER. Close clinical surveillance of all women taking estrogens is important. Adequate diagnostic measures including endometrial sampling when indicated, should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal vaginal bleeding. There is currently no evidence that the use of “natural” estrogens result in a different endometrial risk profile than “synthetic” estrogens at equivalent estrogen doses. (See WARNINGS, malignant neoplasms, Endometrial cancer.) CARDIOVASCULAR AND OTHER RISKS Estrogens with and without progestins should not be used for the prevention of cardiovascular disease. (See WARNINGS, Cardiovascular disorders.) The Women’s Health Initiative (WHI) study reported increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women (50 to 79 years of age) during 5 years of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone acetate (MPA 2.5 mg) relative to placebo. (see CLINICAL PHARMACOLOGY, Clinical Studies.) The Women’s Health Initiative Memory Study (WHIMS), a substudy of WHI, reported increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 4 years of treatment with oral conjugated estrogens plus medroxyprogesterone acetate relative to placebo. It is unknown whether this finding applies to younger postmenopausal women or to women taking estrogen alone therapy. (See CLINICAL PHARMACOLOGY, Clinical Studies.) Other doses of conjugated estrogens with medroxyprogesterone acetate, and other combinations and dosage forms of estrogens and progestins were not studied in the WHI clinical trials and, in the absence of comparable data, these risks should be assumed to be similar.
    [Show full text]